Biogen beat first-quarter profit and revenue expectations on Thursday, as strong demand for its rare disease drugs helped offset declining sales of its multiple sclerosis medicines. The drugmaker has ...

The Biogen/Eisai and Lilly drugs are based on similar mechanisms, reducing the accumulation of amyloid beta (Aβ) plaque in the brain. Aβ is a protein that is said to be the primary cause of the ...

14 analysts have shared their evaluations of Biogen (NASDAQ:BIIB) during the recent three months, expressing a mix of bullish and bearish perspectives. The following table summarizes their recent ...

Neomorph contributes expertise in targeted protein degradation, while Biogen applies its leadership in disease biology and drug discovery to advance this promising approach toward clinical ...

The companies will use Sangamo’s proprietary zinc finger protein (ZFP) technology delivered via adeno-associated virus to change the expression of genes involved in these diseases. Biogen will ...

Biogen has ducked out of a four-year-old collaboration ... It inhibits the nuclear export protein exportin-1 (XPO1), the same target as Karyopharm's approved cancer therapy Xpovio (selinexor ...

Leucine-rich repeat and immunoglobulin-like domain-containing protein 1 (LINGO-1), which was discovered by Biogen, 16 suppresses oligodendrocyte differentiation, axonal regeneration, and neuronal ...

Biotech company Biogen (NASDAQ:BIIB) will be announcing earnings results tomorrow before the bell. Here’s what you need to know. Biogen beat analysts’ revenue expectations by 1.8% last quarter ...

With a market cap of $17.4 billion, Biogen Inc. (BIIB) is a global biotechnology leader focused on discovering, developing, and delivering innovative therapies for serious neurological and ...

Biogen’s Skyclarys (omaveloxolone) has been approved by the Medicines and Healthcare products Regulatory Agency (MHRA) as the first treatment for patients aged 16 years and older with the rare ...

Biogen BIIB and partner Eisai announced that ... more pronounced in people who have a certain form of the gene for the protein apolipoprotein E called ApoE4. Eisai requested the CHMP to re-visit ...